Norwood announces Virosome's successful completion of phase 1 flu trial

By Elaine Rigoli

Tampa, Fla., May 12 - Norwood Immunology Ltd. announced what it called important progress in the clinical trial program of Virosome Biologicals Ltd., the company that Norwood has an option to acquire from Netherlands-based Bestewil Holding Ltd.

Norwood Immunology said Solvay Pharmaceuticals has successfully concluded a phase 1 clinical trial with the intranasal influenza vaccine, triggering a milestone payment to Virosome Biologicals. Virosome Biologicals' adjuvanted virosome technology is licensed to Solvay Pharmaceuticals in the field of intranasal influenza vaccines, according to a news release.

Solvay is responsible for clinical trials and development and commercializing of the vaccine and will continue to test the vaccine in phase 2 clinical trials, the release said.

Based in Victoria, Australia, Norwood Immunology is focused on technologies and therapies to rejuvenate activity of the immune system, through re-growth of the thymus, improvements in bone marrow function and enhancement of t-cell functionality.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.